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Summary 
13  patients  with  human  immunodeficiency  virus  type  1 infection  class  II-IV,  but  without 
opportunistic  infection  or  neoplasm,  received  6  /zg  (3.6  x  104  IU)  of polyethylene  glycol 
recombinant  human  interleukin  2 (PEG II.-2) intradermally  twice a week for 4 mo and were 
then followed for an additional 6 mo. Clinical,  immunological, and viral parameters were monitored 
in the patients, all of whom were taking zidovudine. The cutaneous administration of PEG IL-2 
resulted in an indurated  zone resembling a delayed-type hypersensitivity response of 26  _+  1- 
mm diameter  (676 mm z)  at  72-96 h  after injection throughout  the 4 mo of administration. 
This dose, which was appreciably lower than in most previous trials,  was not associated with 
local or systemic toxicity.  No increase in the viral burden of circulating  leukocytes or plasma 
occurred. A number of immunological functions were stimulated by this course of therapy. All 
patients demonstrated high levels of lymphokine-activated killer cell activity by cells freshly removed 
from the circulation and in the absence of in vitro exposure to IL-2. Natural killer cell activity 
was also enhanced.  Limiting dilution analysis revealed an increase in the frequency of IL-2-responsive 
cells from abnormally low to levels above normal during the course of injections. In a subgroup 
of four patients with  >--400 CD4 + T  cells/#l at entry, there was a trend to sustained increases 
in CD4 + T cell numbers. However, this increase did not reach statistical  significance.  This subset 
of patients also exhibited higher proliferative responses to phytohemagglutinin as mitogen, Several 
of these effects persisted for 3-6 mo after cessation of therapy. In conclusion, low-dose IL-2 regimens 
lead to sustained immune enhancement  in the absence of toxicity. We suggest pursuit  of this 
approach  for further  clinical  trials both as prophylaxis  and  therapy. 
T 
he loss of CD4 § T cells during the course of HIV-1 in- 
fection is accompanied by a reduction in IL-2 (1), a prox- 
imally situated lymphokine required for both cellular and hu- 
moral immunity (2). As a result, life-threatening  opportunistic 
infections and neoplasms ultimately supervene (3, 4). Although 
antiretroviral  agents  and  specific  prophylactic  agents  have 
slowed progression of opportunistic infection, the morbidity 
and mortality  rates  remain  high  (5,  6). 
It has been shown that  in vitro addition  of IL-2 to cells 
from HIV-l-infected patients can correct a number of their 
immunological abnormalities,  enhancing antigen and mitogen 
responsiveness and NK cell function (7-12). Based on these 
findings there was interest in treating HIV-l-infected patients 
with IL-2 in vivo. Early clinical  trials used IL-2 from a variety 
of biological sources and at varied dosing regimens.  There 
was short-term improvement in some parameters of immune 
function such as delayed-type hypersensitivity (DTH) 1 and 
CD4 § T cell count, but no overall reconstitution of the im- 
mune system (13-18).  In these early trials,  patients had ad- 
vanced HIV disease, mostly AIDS, and antiretroviral therapy 
was not yet available. There was dose-dependent toxicity with 
IL-2 treatment, as had been seen in cancer trials using IL-2 (19). 
Recombinant human IL-2 (rhIL-2)  is now available and is 
of high biological activity (20). We have demonstrated that 
rhIL-2  given in much lower doses by the intradermal  route 
can  modify local  and  systemic immunity  in  lepromatous 
This work has been presented  in part at the Eighth International Conference 
on AIDS/Third STD World Congress, Amsterdam, the Netherlands, July 
1992. 
1 Abbreviations used in thistmper: DTH, delayed-type  hypersensitivity; PEG, 
polyethylene glycol. 
483  J. Exp. Med. ￿9  The Rockefeller  University Press ￿9 0022-1007/93/02/0483/10 $2.00 
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tion into the skin of CD4 + and CD8 + T  cells, monocytes, 
and Langerhans cells, and results in a significant reduction 
in  the mycobacterial burden without  II.-2  toxicity. 
More recently, we have reported that  a  single low dose 
(10/~g;  180,000 IU) of rhlL-2 given to HIV-l-positive pa- 
tients can reconstitute their DTH skin test reactions when 
given at a site distant from that of Ib2 administration (23). 
In addition, in a 1-mo trial with 10/zg rhIL-2 (180,000 IU) 
given daily by the intradermal route, both local cell emigra- 
tion in response to IL-2 and systemic immune responses were 
enhanced, and these changes were evoked in the absence of 
toxicity (24, 25). The use of polyethylene glycol rhlL-2 (PEG 
Ib2), 1 which has a plasma clearance 15-fold lower than un- 
modified rhIL-2, allowed administration only twice a week 
(23,  24,  and PEG IL-2 Investigator's brochure,  Cetus  On- 
cology, Chiron Corp., June 1, 1990). A dose of 6 ~g (36,000 
IU) resulted in larger DTH reactions than unmodified rhIb2 
and increased NK cell and LAK cytotoxicity without  IL-2 
toxicity (25).  In these multiple-dose studies,  patients  were 
required to take zidovudine because of the possibility that 
II_,2 would increase viral replication in T  cells.  In light  of 
the evidence that low-dose PEG II.-2  could be given safely 
and led to enhancement  of immune function,  we initiated 
a  4-too study that  will  now be reported. 
Materials and Methods 
Patients.  16 HIV-l-seropositive patients were recruited from a 
cohort of patients followed at The Rockefeller University Hospital 
in a longitudinal study (26),  or were self-referred  after learning 
of our trial from friends or through the protocol listings  in the 
AIDS Treatment Registry in New York City and in the National 
Institutes of Health AIDS database. Patients were included in the 
study if they met the following criteria:  CD4 + T  cell count of 
>1100/zl (one patient had CD4 ~ T cell count of 64/#1 at entry), 
no active opportunistic infection or neoplasm requiring systemic 
chemotherapy, and no other immunomodulatory drugs within 12 
wk of study entry. All patients were required to take zidovudine, 
at least 300 mg daily, because of the possible risk of enhanced HIV-1 
replication. The protocol was  approved by the Institutional Re- 
view Board of The Rockefeller University Hospital, and all pa- 
tients gave written informed consent. Patients were seen in the 
outpatient unit of The Rockefeller University Hospital. 
Study Design.  At baseline  evaluation,  all patients underwent 
history and physical examination. Laboratory evaluation  included 
complete blood count, differential, and routine biochemical profile. 
CD4 +,  CD8 +,  and CD3 § T  cells were enumerated.  DTH re- 
sponses  to control antigens were assessed using Candida albicans 
(Connaught Laboratories, Inc., Swiftwater, PA) and tetanus toxoid 
(aluminum phosphate adsorbed; Wyeth Laboratories, Inc., Marietta, 
PA), 0.1 ml each, by intradermal injection to the forearm. DTH 
responses to HIV-1 antigens were measured using the HIV-1 im- 
munogen skin test, an envelope-depleted,  killed virus preparation 
(a generous gift of Immunization Products, Ltd., Horsham, PA), 
10/~g in 0.1 ml by intradermal injection. All DTH responses were 
read at 48-72 h. The size of the response was expressed as the product 
of the two greatest diameters (in mm2). Selected DTH sites were 
biopsied using a 4-mm punch.  Immunohistochemistry was per- 
formed on these sections  as previously described (25). 
After enrollment, patients received 36,000 IU PEG IL-2 (Cetus 
Oncology Division, Chiton Corporation, Emeryville, CA) twice 
weekly on a Monday/Thursday or Tuesday/Friday schedule for up 
to 4 mo at the outpatient unit of The Rockefeller University Hos- 
pital. The drug was given by intradermal injection to rotating sites 
in the skin of the back. Patients were queried for evidence of tox- 
icity and examined at each visit. Clinical laboratory parameters  as 
well as selected in vitro analyses were repeated at 5 wk, 2 mo, and 
4 mo of PEG IL-2 therapy, and in follow-up at 3 and 6 too. Skin 
tests were repeated at 5 wk, 2 mo, and 4 months of therapy,  and 
3 mo after completion of therapy. 
PEG Ib2.  rhlb2 is produced by Escherichia coli into which the 
cDNA coding for human IL-2 has been cloned. It has similar phys- 
ical and biological properties compared to native IL-2 (20). rhlL-2 
(Cetus Oncology, Chiton Corp.) has a specific activity of 18  x 
106 IU/mg.  PEG IL-2 is a modified form of rhlL-2 in which the 
polymer is covalently attached to rhlL-2. It has a plasma clearance 
10-fold  lower  than  unmodified rhlL-2  (PEG IL-2 Investigator's 
brochure,  Cetus  Oncology, Chiron Corp., June  I,  1990).  The 
specific activity of PEG  Ib2  used  in  this  study was  6  x  106 
IU/mg. 
In Vitro Analysis.  Approximately 60-75 ml of peripheral blood 
was collected in heparinized tubes.  After removal of the superna- 
tant plasma,  PBMC were obtained by centrifugation over Ficoll- 
Hypaque (Pharmacia Fine Chemicals,  Piscataway, NJ), and resus- 
pended in RPMI 1640, 2 mM glutamine, 100 U/ml penicillin,  100 
mg/ml streptomycin (Gibco Laboratories, Grand Island, NY) with 
10% normal human serum (Bioce11, Cardon, CA) as previously 
described (25).  Serum and plasma  were prepared in  a  standard 
manner. 
Cytotoxicity Assays.  These were performed using a 51Cr (New 
England Nuclear, Boston, MA) release assay at various E/T ratios 
in triplicate as previously described (25). NK cell activity was de- 
termined using StCr-labeled K562 cell targets,  and LAK (27) cell 
activity assays used SlCr-labeled Daudi cell targets. Effector cells 
were either fresh PBMC on the day of isolation (NK and LAK 
assays) or were cells that had been cultivated in vitro for 5 d with 
or without rhlb2 at 600 IU/ml (3.3 ng/ml) (LAK assays). Results 
are expressed as percent specific SlCr release as calculated from the 
following formula: 100x  [(mean cpm experimental -  mean cpm 
spontaneous release)/(mean cpm total release  -  mean cpm spon- 
taneous release)]. Values shown are mean  _+  SEM for all patient 
samples at a specified E/T ratio, and at the time point indicated. 
Limiting  Dilution Analysis.  The frequency of circulating Ib2- 
responsive cells was determined using a limiting dilution analysis 
of PBMC after the method of Lefkovitz (28). In a 96-well plate, 
5  x  104 irradiated feeder cells (patient PBMC) were added per 
well, and fresh PBMC were added at 2  x  104 followed by a se- 
ries of twofold dilutions in the presence of 28,000 IU/ml (155 ng/ml, 
or 10 nM) rhlL-2.  After 10 d, cells were pulsed with [3H]thymi- 
dine (ICN Radiochemicals,  Irvine, CA). 18 h later, cells were har- 
vested, and [3H]thymidine  uptake was measured.  Responder wells 
were defined as those with [3H]thymidine uptake of greater than 
the mean plus three times the SD for cells with media alone. The 
frequency of responsive  cells was then converted to a percentage 
for further statistical analysis. PBMC from normal laboratory volun- 
teers were analyzed in the same manner. 
Lymphocyte Transformation Tests.  These assays were performed 
using phytohemagglutinin (PHA-P; Difco Laboratories,  Detroit, 
MI) as mitogen in a 3-d [3H]thymidine uptake assay as previously 
described (25). The killed HIV-1 immunogen was also tested for 
its ability to stimulate lymphocyte proliferation at the following 
concentrations: 5.0, 0.5, and 0.05 gg/well, or 25,  2.5, and 0.25 
/~g/ml  in a 7-d assay. 
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lyzed by flow cytometry as previously  described (25), and used the 
following  fluorochrome-conjugated  antibodies: Leu-4  (CD3), Leu-3a 
(CD4), Leu-2a (CDS), HLA-DR (MHC class II), Leu-11c  (CD16), 
the low affinity IL-2R (anti-Tac, CD25), Leu-M3 (CD14) (all from 
Becton Dickinson &  Co.,  Mountain  View, CA),  and NKH-1 
(CD56) (Coulter Immunology, Hialeah, FL). For all antibodies 
except Leu-M3, the population analyzed  was gated by scatter  criteria 
as the lymphocyte population. For Leu-M3 analysis, total PBMC 
(lymphocytes plus monocytes) were used. 
Viral Culture.  HIV-1  burden in PBMC as well as plasma was 
determined in a coculture system with normal lymphoblasts using 
HIV p24 ELISA (DuPont Co., Wilmington, DE) as the endpoint. 
This was done in bulk and in 10-fold  dilutions for end-point anal- 
ysis as previously described (25) in a method adapted from Ho et 
al. (29) and Coombs et al. (30). Viral load was determined by time 
to positive bulk culture as well as the tissue culture infectious dose 
by endpoint dilution. 
StatisticaIAnalysis.  Results of all in vitro analyses  are expressed 
as the mean  _+  SEM. CD4 § T cell counts and limiting dilution 
analysis of the frequency of Ib2-responsive cells were analyzed by 
Mann-Whitney U-Wilcoxon rank sum W test. Results of cytotox- 
icity assays were tested by analysis of variance, comparing values 
of samples receiving identical in vitro treatment (cells analyzed on 
the day of isolation; cells cultivated with or without Ib2 in vitro) 
from baseline to PEG IL-2 treatment  and follow-up timepoints. 
Results 
Patient  Characteristics  and Clinical  Course 
16 patients, 26-65 yr old, Center for Disease Control class 
II-IV (31, 32),  were enrolled in the study (Tables 1 and 2). 
Table  1.  Patient Characteristics at Enrollment 
There were 14 men and 2 women. Five patients (nos.  1, 2, 
3, 5, and 10) had received rhlb2 or PEG II,-2 in prior studies 
at least  12 wk before study entry. In the current study 13 
patients received at least eight injections (21  _+  2 injections 
per patient, mean _+  SEM) over a 4-mo period and were in- 
cluded for analysis. Of the three patients who received less 
than eight injections, one (no. 15) dropped out immediately 
and one (no. 6) 3 wk after enrollment. One patient (no.  10) 
developed a fever of unknown origin and was taken off  zidovu- 
dine by his private physician after 3 wk on study. He was 
therefore ineligible to receive further PEG II-2. 
Of the 13 patients included in the analysis, 10 completed 
at least  12 wk of treatment. Of the three patients who re- 
ceived <12 wk of PEG I1-2, patient no. 14 developed grade 
1 (mild) anemia and his zidovudine was stopped by his per- 
sonal physician at 8 wk of study. He therefore could not re- 
ceive further PEG I1-2. Patient no. 16, whose entry CD4 § 
T cell count was 64//xl, developed mild Pneumocystis carinii 
pneumonia at week 8 of the study and after a brief hospital- 
ization completed his treatment as an outpatient. The third 
patient (no.  13) entered the study at the midpoint but re- 
ceived all doses from the time of entry until the completion 
of the study. 
Adverse Events 
Of the 13 initial patients, two (nos.  9 and 11) reported 
a mild flu-like illness with headache,  low grade fever, and 
myalgias for 1-2 d over the 4omo treatment period. Patient 
no. 5 had intermittent, transient, and asymptomatic hypo- 
Entry CD4 + 
Patient  Age  Sex  CDC class  Diagnosis  T cells  Medications 
per jul 
1  36  M  IVC.2  OHL  364  ZDV,  ACV 
2  36  M  II  ASX  304  ZDV,  ACV,  AP 
3  61  M  II  ASX  360  ZDV 
4  33  M  IVC.2  Thrush  210  ZDV,  ACV,  TMP-SMZ 
5  26  M  II  ASX  459  ZDV 
6  37  M  IVC.2  Thrush  122  ZDV,  ACV,  TMP-SMZ 
7  38  M  IVC.2  OHL  309  ZDV, ACV 
8  65  M  II  ASX  443  ZDV 
9  28  F  II  ASX  499  ZDV 
10  37  M  IVC.2  Thrush  300  ZDV, TMP-SMZ 
11  29  M  II  ASX  414  ZDV 
12  27  M  II  ASX  352  ZDV 
13  41  F  III  PGL  441  ZDV 
14  57  M  II  ASX  120  ZDV, ACV,  DAPSONE 
15  39  M  IVA  ARC  494  ZDV 
16  34  M  IVC.2  OHL  64  ZDV, TMP-SMZ 
Diagnosis: ASX, asymptomatic;  PGL, persistent generalized  lymphadenopathy;  Thrush, oral candidiasis;  OHL, oral hairy  leukoplakia; ARC, AIDS- 
related complex. Medications: ZDV, zidovudine; ACV, acyclovir; AP, aerosol pentamidine; TMP-SMZ, trimethoprim-sulfamethoxazole. 
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of Doses PEG IL-2 
(>4  DTH  mm) 
Total no. of 
Patient  Candida  Tetanus  Prior IL-2  doses/total wk 
1  -  +  Y  27/16 
2  +  +  Y  27/16 
3  -  +  Y  26/16 
4  +  +  N  9/12 
5  -  +  Y  23/16 
6  -  +  N  5/3 
7  +  +  N  21/12 
8  +  -  *  N  32/16 
9  +  +  N  28/16 
10  +  +  Y  5/3 
11  +  +  N  24/16 
12  +  +  N  25/15 
13  +  +  N  12/6 
14  -  +  N  12/8 
15  ND  ND  N  0/0 
16  -  -  N  11/16 
* This patient had a late positive DTH response to tetanus toxoid (see 
text). 
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Figure  1.  T cell profile over the course of  PEG IL-2 treatment and follow- 
up. Patients with entry CD4+  T  cells ~400/~1 (e, n  =  4), or <400/~1 
(A,  n  =  7).  Values  shown are mean  _+  SEM. 
glycemia (glucose, 40-45 mg/dl) over the period of observa- 
tion,  including at the 6-too posttreatment visit.  As noted 
above, patient no. 14 developed grade 1 anemia. None of these 
symptoms or signs could be clearly related to the administra- 
tion of PEG IL-2. 
Local Response 
At the site of injection we observed an area of induration 
and erythema clinically similar to a DTH response (21, 23, 
25). The average size of the reaction was 26  _+  1 mm in di- 
ameter (mean  _+  SEM) at 72-96 h after injection, and this 
area of 676-mm  2 did not vary appreciably during the course 
of PEG Ib2 injections. The injections were well tolerated, 
with only mild pruritus  at the injection sites. 
Hematologic Responses 
During the course of PEG IL-2 treatment, there was an 
upward  trend of the  CD4 +  T  cell count,  which  did not 
reach statistical significance.  When patients were stratified 
into  groups  based  on  entry  CD4 +  T  cell  counts  per 
microliter of >--400 or <400 (Fig.  1), there was a more pro- 
nounced increase in CD4 + T  cells in the group of patients 
with entry counts >--400/#1. This increase was 20-39% above 
baseline during treatment and at 3 mo of follow-up. By 6 
mo of follow-up the CD4 § T  cell count declined to 13% 
above baseline. However, the number of patients in this subset 
was too small to demonstrate statistical significance by Wil- 
coxon rank sum analysis. In the group with entry CD4 § T 
cell numbers <400//.d, CD4 + T cell counts were maintained 
but  did not increase.  The overall  or stratified CD8 §  and 
CD3 + T cell counts did not change significantly from base- 
line over the course of PEG I1:2 treatment. Overall total white 
blood cell count and lymphocyte counts were also unchanged. 
Cytotoxicity 
LAK Cell Activity.  LAK cell activity is assayed by the 
ability of PBMC to kill Daudi cell targets. Cells from our 
patients at baseline,  as well as from normal controls, failed 
to show significant LAK activity when freshly isolated or 
when cultivated in the absence of IL-2. Both normal and pa- 
tient populations expressed high activity after 5 d of cultiva- 
tion in the presence of 600 IU/ml IL-2. 
Significant alterations in LAK cell activity were apparent 
at  2 and 4 mo of PEG IL-2 administration.  During treat- 
ment, freshly isolated PBMC exhibited markedly increased 
LAK activity without in vitro cultivation (p  =0.001  at 4 
mo of treatment; Fig.  2 A).  In fact, PBMC cultivated for 
5 d in the absence of Ib2 still demonstrated maximal ability 
to kill Daudi targets ~  <  0.001 at 2 mo of treatment; Fig. 
2 B). These effects persisted at 3 and 6 mo of follow-up (p 
<0.05 for fresh PBMC and p <0.001 for cultivated cells).  It 
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Figure  2.  Enhanced  LAK cell activity 
during PEG I1:2 treatment and follow-up. 
Patient PBMC were assayed  (A) fresh on 
the day of isolation (mean, n  =  7) or (B) 
after 5 d  of cultivation with (mean,  n  = 
9) or without  (mean, n  =  8) rhI1:2 (600 
IU/ml  or  3.3  ng/ml)  in  vitro.  (Open 
symbols) Cells that have received no rhI1:2 
in vitro. (0) Mean values for PBMC stimu- 
lated by I1:2 in vitro for all patients at all 
time points.  Values  shown  are  mean  _+ 
SEM. 
therefore appeared that PEG IL-2 enhanced LAK cell activity 
in vivo. 
NK Cell Activity.  We examined the ability of fresh PBMC 
to kill the K562 cell, a NK cell target (Fig. 3). Enhancement 
of NK cell activity was evident at 2 mo (p  =  0.001), 4 mo 
(data not shown), and persisted at 3 mo of follow-up (p < 
0.001). By 6 mo of follow-up, this enhancement was no longer 
seen. 
Frequency of lL-2-responsive Cells 
Limiting dilution analysis was performed to assess the per- 
centage of IL-2-responsive cells  in the circulation  as deter- 
mined by proliferative responses (Fig. 4). In normal controls 
(n  =  7) the percentage of IL-2-responsive cells among PBMC 
is 1.88  _+ 0.66% (mean  +_ SEM). In our patients at baseline 
the percentage of IL-2-responsive PBMC was reduced more 
than  fourfold to 0.42  +  0.08%.  This increased at 2 and 4 
mo of treatment, and at 4 mo, the percentage of Ib2-responsive 
cells was 4.88  +_  1.81%, an increase of >2.5-fold above the 
value for controls, and >10-fold above patient baseline values 
(p  =  0.0008).  This effect subsided completely by 3 mo of 
follow-up. The phenotype of the Ib2-responsive population 
has not  as yet been ascertained. 
Lymphocyte Proliferative Responses 
The ability of PBMC to proliferate in response to mitogen 
(PHA) or HIV-1 antigen was examined. After PEG II,-2 ad- 
ministration and through 3 mo of follow-up, there was a 1.5- 
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Figure  3.  Enhanced NK cell activity over the course 
of PEG II:2 treatment  and follow-up (mean,  n  =  10). 
Values  shown  are mean  _+  SEM. 
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Figure  5.  Lymphoproliferative responses  to PHA 
during PEG IL-2 treatment and follow-up.  Lympho- 
cyte proliferative responses to PHA during treatment 
and foUow-up in all patients (left) and in patients with 
entry  CD4 +  T  cells  ~400//A (right). Stimulation 
index equals mean cpm stimulated ceUs/mean cpm cells 
in media alone. Values shown are mean _+ SEM. Du- 
ration of PEG IL-2 administration indicated by open 
bars. 
fold increase in proliferative response to PHA, but this did 
not reach statistical significance (Fig.  5,  left). In the group 
of patients with entry CD4 § T  cell counts >~400/~1, how- 
ever, this increase was significant (Fig.  5, right) and was sus- 
tained  at  the 3-mo follow-up evaluation. 
Proliferative responses to the HIV-1 antigen in vitro were 
quite low at all time points, but did increase fivefold in all 
patients and threefold in the group with entry CD4 + T cell 
counts i>400//zl  (Table 3). At follow-up these values returned 
to baseline.  These responses were only observed at the higher 
antigen  dose level of 25/~g/ml. 
PBMC Phenotype.  A  number  of other parameters  were 
followed and were essentially unchanged. These included the 
phenotype  of peripheral  PBMC  as  determined  by immu- 
no  fluorescence  and flow cytometry, other than in the CD4 § 
T cells noted earlier.  There was no significant change in the 
gated lymphocyte population in total T  cells (CD3 +),  NK 
cells (CD56+), class II MHC-expressing cells (HLA-DR.+), 
or in cells  that  express the low affinity IL-2 receptor,  p55 
(CD25).  There was also no change in monocyte numbers 
(CD14 §  (data  not  shown).  This  was  true  for the  entire 
group of patients  as well as for the stratified groups based 
on entry CD4 T  cell counts. 
Quantitation of HIV-1 Burden.  There was no consistent or 
sustained change in the titer of cell-associated  virus or plasma 
Table  3.  Proliferative  Responses  to HIV-I  Antigen 
Timepoint  All patients 
Entry CD4 + 
T  cells 
(~>400//zl) 
Baseline  0.5  +  0.1  0.5  _+  0.2 
2  mo  PEG  ILo2  1.2  _+ 0.3  1.2  +_ 0.1 
4  mo  PEG  ILo2  2.4  +_  0.7  1.5  _+ 0.3 
3  mo  follow-up  0.9  _+ 0.4  0.6  _+ 0.4 
Values shown are mean _+ SEM  of stimulation indices  at 25 #g/ml of 
antigen. Stimulation index is mean cpm stimulated cells/mean cpm cells 
in media alone. 
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Figure  6.  Effect of PEG IIr  on the DTH 
response to tetanus toxoid. This patient was 
anergic to intradermal tetanus toxoid 2 d after 
injection. On day 3 a single dose of 0.5 #g or 
2,000 IU PEG IL-2 was given at a distant site. 
Within 24 h there was erythema at the forearm 
tetanus  toxoid  site,  and  by  48-72  h  after 
receiving PEG Ib-2, the tetanus site became in- 
durated. This response waned over the next few 
days. 
viremia during PEG IL-2 treatment and follow-up (data not 
shown). All patients had virus isolated from PBMC at entry 
(TCID,  104  to  5  x  106) and  three patients  had negative 
PBMC viral cultures at one time point during therapy, but 
follow-up cultures showed PBMC titers comparable to those 
at baseline.  There was low titer plasma viremia (TCID,  1.0 
and 0.1  ml) in up to three patients at any time point. 
DTH Responses 
The enhancement in the size of DTH reactions by rhlb2 
and PEG IL-2 has been commented upon in previous publi- 
cations (21, 23,  25).  Examples of enhancement of response 
to tetanus toxoid were noted in this study, including one late 
positive tetanus toxoid DTH response. This patient (no. 8) 
was initially anergic at 48 h  to tetanus toxoid administered 
to the volar forearm, and his first dose of PEG IL-2 was ad- 
ministered to the back at that visit. He then demonstrated 
a typical DTH response at the tetanus site that peaked at 3 d 
after his dose of PEG IL2. The late positive tetanus toxoid 
DTH response is shown in Fig. 6, in a patient who partici- 
pated in a l-too PEG IL-2 trial (25).  His originally anergic 
tetanus site became strongly positive only after his first and 
lowest dose (0.5/~g or 2,000 IU) of PEG IL2 was given in 
the dose escalation phase of the study. 
The HIV skin test was performed in 12 of 13 patients. 
Only one (no. 10) had a positive, 4-mm diameter response 
before PEG IL-2. Late positive HIV skin tests were observed 
after the first dose of PEG IL-2 in three additional patients. 
This occurred only in patients after punch biopsy of what 
were considered negative sites at 48-72 h after placement of 
the HIV skin test. In these individuals, 10-20-mm-diameter 
areas of erythema and induration occurred around the biopsy 
site. At 5 wk, 2 and 4 too, and at 3 mo of follow-up, the 
HIV skin tests were uniformly negative. 
Discussion 
The use of low-dose PEG IL-2 (36,000 IU) given twice 
weekly by intradermal injection has resulted in sustained en- 
hancement of a number of immune parameters. This has oc- 
curred without  any apparent  toxicity related to  IL2  and 
without evidence of any change in viral burden. Two indices 
of systemic immunity were particularly enhanced. First, the 
percentage of PBMC that proliferate in response to IIr  in 
a limiting dilution assay, was increased 12-fold. The percentage 
of IL-2-responsive cells returned to baseline upon withdrawal 
of the lymphokine. Second, there were striking increases in 
the activity of LAK cells, and to a lesser degree in the ac- 
tivity of NK cells.  Cells removed from the circulation ex- 
hibited high levels of LAK cytotoxic activity without fur- 
ther in vitro incubation with IL-2. In fact, incubation with 
IL-2 for 5 d failed to enhance activity above that expressed 
by cells that had been incubated without IL-2. Of interest 
was the persistence of increased LAK and NK activity many 
months beyond the cessation of therapy, suggesting a long- 
lived population. Both of these parameters of immunity were 
enhanced in all patients irrespective of their original CD4 § 
T  cell counts. 
There were, however, IL-2-induced effects that appeared 
to require a critical number of preexisting CD4 + T  cells. 
This was most evident in the ability of IL-2 to increase and 
maintain CD4 + T cells in patients with entry CD4*  T cell 
counts of >~400/#1 during the 4-mo trial. Due to the small 
number of patients in this subgroup,  this change was not 
statistically  significant.  In  contrast,  patients  with  <400 
CD4 + T  cells per microliter at the outset failed to exhibit 
increased numbers, but maintained their original levels. Simi- 
larly,  the enhanced proliferative responses to the mitogen, 
PHA, were most apparent in patients with >t400 CD4 + T 
cells per microliter at entry. In studies with Dr. M. J. McElrath 
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patients with CD4 + T cell counts of <50/#1 fail to generate 
maximal indurative responses to intradermal PEG I1:2 itself, 
nor can their DTH reactions be enhanced. Yet, during PEG 
I1:2 treatment,  three of six patients in this series cleared or 
improved their chronic oral candidiasis (our unpublished data). 
It should be noted that  all patients were taking zidovu- 
dine (ZDV) during PEG IL-2 administration.  ZDV may have 
blunted  the cellular response to the lymphokine.  Our  ex- 
perience with the HIV-l-infected patients differed from that 
with leprosy patients (22) and from the experience of others 
treating patients with cancer and after bone marrow trans- 
plantation with low to moderate doses of I1:2 for prolonged 
periods (33-37). Patients with lepromatous leprosy who re- 
ceived low-dose (10/xg or 180,000 IU BID) intradermal rhI1:2 
developed both lymphadenopathy in the regional nodes of 
the axiUa (injection sites were in the upper back), and brisk 
elevations in the number of CD4 + and NKH-1 + (NK) lym- 
phocytes in the circulation, which were not seen in the HIV- 
1-infected population.  Alternatively,  the dose of PEG I1:2 
may have been too low to cause an increase in the number 
of NK cells, since data from cancer chemotherapy and bone 
marrow transplantation  trials show significant expansion of 
NK cell numbers, and in the cancer trials (35) this expansion 
was I1:2 dose dependent. 
In a recent trial of rhlL-2 in patients with early HIV infec- 
tion,  CD4 §  T  cells  >--400/#1 and  no  prior  antiretroviral 
therapy),  a  relatively  high  dose  of  I1:2  (1.5-12  ￿  106 
IU/m2/d,  or  83-667  /zg/m2/d)  was  given  by  24-h  con- 
tinuous intravenous infusion 5 d/wk for 1 mo plus ZDV with 
the  expected  I1:2  toxicities  (38).  Transient  increases  in 
CD4 + T  cell numbers were seen during  therapy.  Interest- 
ingly, many of these patients showed sustained elevations of 
CD4 + T  cells  for up to  18 mo of follow-up, but as these 
patients were newly started on antiretroviral therapy the rel- 
ative contributions of I1:2 and ZDV in this rise are not clear. 
During I1:2 treatment, enhanced NK and LAK activity were 
demonstrated, but only in the toxic, high-dose range (6-12 
￿  106 IU or 333-667/~g/m2/d).  In addition there was a de- 
crease in HIV-1 provirus in PBMC as determined by semi- 
quantitative  PCR (39).  In contrast  to this  study, we have 
demonstrated significantly enhanced NK and LAK activity 
at nontoxic doses of II:2.  These increases  were much more 
dramatic in our patients  at 2 and 4 mo of treatment  than 
was observed in our 1-mo trial at the same doses (25). When 
these data are taken in aggregate with the increased frequency 
of I1:2-responsive  cells among PBMC, and with the improved 
lymphoproliferative responses, both greater at 4 than 2 mo 
of therapy, there is a suggestion of greater cumulative effect 
with low-dose PEG I1:2 over a long course of therapy. Longer 
term trials are needed to determine the maximal immune en- 
hancement  achievable  with I1:2.  This finding is supported 
by recent studies of low- to intermediate-dose IL-2 given by 
continuous infusion to patients with advanced cancer (0.5-6.0 
x  105  IU  or  3.3-40  #g/m2/d)  (34,  35)  and  after  bone 
marrow transplantation  (2  x  10  s IU or 13 #g/m2/d)  (33). 
In these studies, expansion of the NK cell population increased 
progressively over a 3-too course of II.,2 treatment, without 
any indication that a maximum had been reached. There was 
also enhancement  of NK and LAK activity in vitro. There 
has not been evidence of enhanced LAK activity in vivo in 
other reports. 
Further studies are needed to correlate the enhanced im- 
munological parameters with the incidence and severity of 
opportunistic infections. Based upon our present results and 
data from animal experiments  (40),  we suspect that  long- 
term I1:2 therapy represents a rational prophylactic agent that 
would prolong  the disease-free state.  The  efficacy of such 
therapy will probably be associated with the initial levels of 
CD4 + T  cells,  and its use in earlier stages of HIV-1 infec- 
tion is suggested.  We consider that therapy can be administered 
easily by the patients  themselves at  home by the subcuta- 
neous route. This could be on a twice weekly schedule with 
PEG I1:2 or daily with rhI1:2. With both preparations,  the 
persisting local indurative response would be an excellent in- 
dication of compliance. Such studies are planned for the near 
future. 
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